260
Participants
Start Date
April 24, 2023
Primary Completion Date
July 15, 2025
Study Completion Date
August 25, 2025
AZD3427
The participants will receive AZD3427 SC injection single dose of either Dose A or Dose B or Dose C every 2 weeks for 24 weeks.
Placebo
The participants will receive SC injection of placebo single dose every 2 weeks for 24 weeks.
Research Site, Vienna
Research Site, Copenhagen
Research Site, Linz
Research Site, Aarhus
Research Site, Prague
Research Site, Prague
Research Site, Berlin
Research Site, Genoa
Research Site, Milan
Research Site, Milan
Research Site, Baltimore
Research Site, Brescia
Research Site, Majadahonda
Research Site, Rock Hill
Research Site, Trieste
Research Site, Seville
Research Site, Toledo
Research Site, Valencia
Research Site, Cologne
Research Site, Marche
Research Site, Frankfurt
Research Site, St Louis
Research Site, Omaha
Research Site, Beverly Hills
Research Site, La Jolla
Research Site, Beijing
Research Site, Changsha
Research Site, Guangzhou
Research Site, Kunming
Research Site, New Haven
Research Site, Edmonton
Research Site, Vancouver
Research Site, Halifax
Research Site, London
Research Site, Ottawa
Research Site, Toronto
Research Site, Montreal
Research Site, Prague
Research Site, Jena
Research Site, Bunkyō City
Research Site, Kasugai-shi
Research Site, Kure-shi
Research Site, Nagoya
Research Site, Sapporo
Research Site, Sunto-gun
Research Site, Toyama
Research Site, Deventer
Research Site, Heerlen
Research Site, Tilburg
Research Site, Bialystok
Research Site, Gdansk
Research Site, Krakow
Research Site, Warsaw
Research Site, Warsaw
Research Site, Wroclaw
Research Site, Gothenburg
Research Site, Huddinge
Research Site, Cambridge
Research Site, Clydebank
Research Site, London
Lead Sponsor
Collaborators (1)
Parexel
INDUSTRY
AstraZeneca
INDUSTRY